{"entity":{"id":"ibi130","kind":"drug","name":"IBI130","aka":[],"tldr":"IBI130 is an experimental antibody-drug conjugate being studied in people with advanced cancer. Its benefit and safety are still being evaluated.","summary":"ASCO 2025 abstract 1102 reports 71 patients treated in the first-in-human study at the December 15, 2024 cutoff. Among 30 efficacy-evaluable TNBC patients across doses, ORR was 50.0% (95% CI 31.3 to 68.7); PFS and duration of response were immature. Grade 3 treatment-related events occurred in 15.5% of the 71 patients; one had grade 1 interstitial lung disease. This is an uncontrolled early cohort, not comparative proof of improved safety or efficacy.","status":"phase-1","asOf":"2026-10-06","links":[{"label":"Publisher abstract","url":"https://doi.org/10.1200/jco.2025.43.16_suppl.1102"},{"label":"ClinicalTrials.gov NCT05923008","url":"https://clinicaltrials.gov/study/NCT05923008"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":["adc"],"targets":["trop2"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct05923008"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"modality":"ADC","payload":"NT1 (camptothecin derivative, TOP1 inhibitor)","mechanism":"Anti-TROP2 antibody linked to NT1, a camptothecin-derived TOP1 inhibitor.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/ibi130/","neighbours":{"technology":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"}],"target":[{"id":"trop2","kind":"target","name":"TROP2","route":"/targets/trop2/"}],"trial":[{"id":"nct05923008","kind":"trial","name":"A Clinical Study of IBI130 for Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors","route":"/trials/nct05923008/"}]}}